Maze Therapeutics (NASDAQ:MAZE) CEO Sells $50,388.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 1,938 shares of the business’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $26.00, for a total transaction of $50,388.00. Following the sale, the chief executive officer directly owned 31,001 shares of the company’s stock, valued at $806,026. This represents a 5.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Trading Down 4.1%

Shares of NASDAQ MAZE traded down $1.06 during trading on Monday, hitting $24.50. 596,266 shares of the company traded hands, compared to its average volume of 727,496. Maze Therapeutics, Inc. has a 1 year low of $9.15 and a 1 year high of $53.65. The company has a 50-day moving average price of $33.41 and a 200-day moving average price of $37.97. The firm has a market capitalization of $1.36 billion, a P/E ratio of -9.68 and a beta of 2.50. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. On average, equities analysts predict that Maze Therapeutics, Inc. will post -2.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Guggenheim lifted their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Wedbush boosted their target price on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $66.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada lifted its stake in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Maze Therapeutics in the 4th quarter worth approximately $39,000. Ameritas Investment Partners Inc. lifted its stake in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Maze Therapeutics in the 4th quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.